News & Updates

Use of sodium–glucose cotransporter-2 inhibitors (SGLT-2i) as first-line treatment for type 2 diabetes (T2D) delivers a comparable risk for myocardial infarction (MI), stroke, and mortality; a lower risk for hospitalization for heart failure (HHF)/mortality and HHF; and a similar safety profile, except for a higher risk for genital infections, when compared to treatment with metformin, a study has found.

Treatment with beta-blockers in hypertension may decrease daily physical activity but not maximal exercise performance, a study has found.

Individuals with a prior COVID-19 infection and who are fully vaccinated against COVID-19 appear to have the greatest immunity to the virus, according to the SIREN* study.